Walk into a nutraceutical raw-material exhibition hall or browse e-commerce platforms and the words "Cistanche extract" are everywhere: one bottle is labeled 1% echinacoside, another 30% or even 50%; one product is used in an everyday solid beverage, while another appears only in health foods and pharmaceuticals. The name is identical, yet the price, efficacy, and regulatory identity may differ several-fold. For purchasers, R&D teams and even ordinary consumers, the question naturally arises: why such a big gap between extracts both called "Cistanche extract"?

The answer is not in marketing language but in the raw material's botanical origin-that is, which species of Cistanche it actually comes from. The Chinese Pharmacopoeia lists two species simultaneously: Cistanche deserticola and Cistanche tubulosa. Both belong to the Orobanchaceae family, genus Cistanche, yet their host plants, growing environments, and active-component profiles differ, leading them down distinctly different application paths. Centering on C. tubulosa, this article unpacks the scientific and industrial logic behind this "same name, different quality" phenomenon.

Cistanche Oral Liquid

I. The first step in telling them apart: the watershed of botanical origin

Mainstream Cistanche raw materials on the market fall mainly into two branches. One is C. deserticola, commonly known as "soft dayun," mainly produced in western Inner Mongolia, Gansu and Ningxia, parasitizing the roots of Haloxylon (saxaul), with an oily, soft texture and relatively high polysaccharide content. The other is C. tubulosa, commonly known as "hard dayun," mainly produced around the Taklamakan Desert south of the Tianshan Mountains in Xinjiang (represented by Hotan and Kashgar), parasitizing the roots of Tamarix (red willow), with a hard texture and dotted vascular bundles visible in the cross-section.

Although both are included under the single medicinal name "roucongrong" and share the traditional actions of "tonifying kidney yang, benefiting essence and blood, and moistening the intestine to relieve constipation," they are listed separately in the Chinese Pharmacopoeia with different quality baselines: for C. deserticola, the total of echinacoside and acteoside (verbascoside) must not be less than 0.30%; for C. tubulosa, the total must not be less than 1.5%-so, by the pharmacopoeia "passing line" alone, C. tubulosa is already five times higher. This is the institutional starting point of "same extract name, yet intrinsically different."

II. The core of the gap: phenylethanoid glycoside content and component profile

The most central active cluster in Cistanche plants is the phenylethanoid glycosides (PhGs), with echinacoside and acteoside (verbascoside, also known as kusaginin) as the two marker monomers-also the indicator components for pharmacopoeial quality control. The reason C. tubulosa is regarded as the core source of "high-activity extract" lies in the pronounced enrichment of these constituents.

In a high-quality C. tubulosa extract, the echinacoside mass fraction can reach 15%–50%, and acteoside about 10%; even at the fresh-material level, the combined echinacoside and acteoside is roughly 1.5–4 g per 100 g. By contrast, in C. deserticola the two combined amount to only about 0.3 g per 100 g, with common echinacoside extract specifications around 1%–4%. This is not a matter of "good versus bad," but a natural division of component profiles:

Cistanche tubulosa

 

Cistanche deserticola

C. tubulosa extract: predominantly phenylethanoid glycosides, lower oligosaccharides, no betaine; high active-constituent content and good water solubility, suited to standardized purification and industrial formulation.

C. deserticola extract: relatively higher oligosaccharides, mannitol and betaine, abundant polysaccharides and a sweet taste; more oriented to daily food therapy and gentle nourishment.

In short, C. tubulosa follows the "high PhGs, targeted efficacy" route, whereas C. deserticola follows the "polysaccharide, daily nourishment" route. It is worth emphasizing that total PhGs also include a series of phenolic glycosides such as isoverbascoside, tubuloside A/B and angoroside; echinacoside and acteoside, though the two most critical and frequently tested indicators, do not represent the full value of C. tubulosa-it is the overall enrichment of this component profile that underpins its market recognition as "high-activity Cistanche." This divide determines all subsequent efficacy emphasis and application choices.

Phenylethanol glycoside is the main active component of Cistanche tubulosa

III. One table to understand them both: a panoramic comparison of tubulosa vs. deserticola extracts

Comparison Dimension	Cistanche tubulosa Extract	Cistanche deserticola Extract
Botanical origin / main producing area	Cistanche tubulosa; mainly produced in Southern Xinjiang, Xinjiang (Hotan, Kashgar); parasitizes the roots of Tamarix (red willow).	Cistanche deserticola; mainly produced in Alxa (Inner Mongolia), Gansu, etc.; parasitizes the roots of Haloxylon (saxaul).
Pharmacopoeia lower limit	Echinacoside + acteoside (verbascoside) ≥ 1.5%.	Echinacoside + acteoside (verbascoside) ≥ 0.30%.
Marker constituents	Very high phenylethanoid glycosides (PhGs); echinacoside may reach 15%–50%, acteoside up to ~10%.	Relatively high polysaccharides, oligosaccharides, mannitol and betaine; PhGs comparatively lower.
Description/taste	Spindle-shaped, hard texture, bitter taste, good water solubility.	Flat-cylindrical, oily and pliable, sweet taste.
Functional emphasis	Tonifies kidney and essence, anti-fatigue, antioxidant, neuroprotection, liver protection.	Moistens intestine and relieves constipation, daily mild nourishment.
Regulatory status	Used only as a medicinal herb; not yet permitted directly in ordinary food.	Listed as medicine-and-food homologous; may be used in ordinary food.
Main applications	Pharmaceuticals, health food, extract export, cosmetic raw material.	Medicinal diet/food therapy, solid beverages, traditional decoction pieces.

Note: Pharmacopoeia indicators are the lower limits for the dried crude herb; after enrichment, monomer content in the extract can be significantly higher than in the herb itself.

IV. Why "high activity" falls to C. tubulosa: how constituents determine efficacy emphasis

Classical Chinese medical texts record that Cistanche "nourishes the five viscera, benefits essence qi, and lightens the body upon long-term use"; modern pharmacology has progressively mapped this tonifying action to the molecular level. Echinacoside and acteoside among the PhGs, together with total Cistanche glycosides, tubuloside B and Cistanche polysaccharides, jointly constitute the pharmacological foundation.

1. Tonifying kidney and essence, anti-fatigue and antioxidant

Backed by its high echinacoside content, C. tubulosa extract stands out in scavenging free radicals and protecting mitochondrial function; it can enhance organismal energy metabolism and relieve physical and mental fatigue, making it a mainstream choice for sports nutrition, workplace anti-fatigue and anti-aging products. Its PhGs are believed to relieve kidney-yang deficiency-related manifestations such as sore/weak waist and knees, cold intolerance and fatigue by regulating the hypothalamic–pituitary–adrenal axis and improving energy metabolism.

Effects of Cistanche-Improve kidney function

Click here to view Cistanche for Kidney disease products

【Ask for more】 Email:cindy.xue@wecistanche.com / WhatsApp: 0086 18599088692 / WeChat: 18599088692

2. Neuroprotection: the most valued differentiated track for C. tubulosa

This is the direction in which C. tubulosa most differs from C. deserticola and has the deepest research footprint. Echinacoside protects dopaminergic neurons from oxidative-stress damage, inhibits neurotoxin-induced neuronal loss and enhances neurotrophic-factor activity; acteoside improves behavioral performance, increases brain dopamine neurotransmitter content and protects synaptic transmission; tubuloside B and campneoside II also show anti-neuronal-apoptosis effects. Together, these four pathways point to: protecting neural cells, promoting their growth and repair, increasing neurotransmitter release and improving cerebral circulation-thereby improving learning and memory and supporting research into adjuvant prevention/treatment of Alzheimer's disease and Parkinson's disease.

3. Liver protection, anti-radiation and multi-target synergy

Total glycosides of Cistanche tubulosa can inhibit liver cancer cells at the early stage of liver cancer 

Total Cistanche glycosides can reduce hepatocyte apoptosis and necrosis and ameliorate liver-tissue injury; echinacoside improves the degree of liver injury, while acteoside raises SOD activity to protect the liver. In addition, total glycosides promote the recovery of SOD activity and nucleic-acid content after radiation exposure; echinacoside exerts endothelium-dependent vasodilation on aortic rings; acteoside inhibits the release of histamine and TNF-α, suggesting anti-allergy potential. These "added values" jointly broaden the application prospects of C. tubulosa extract in liver protection, middle-aged/elderly care, and skin-care and anti-aging scenarios.

By comparison, because C. deserticola is rich in polysaccharides, oligosaccharides, and betaine, it has more traditional advantages in moistening the intestine to relieve constipation, constipation due to blood deficiency and fluid depletion, and daily gentle nourishment. The two have distinct efficacy emphases; what clinical and product development pursue is "precision selection," not simple substitution.

V. Industrial reality: why most extraction feedstock is C. tubulosa

From an industrialization perspective, C. tubulosa plants are fleshy and thick, adaptable and relatively stable in raw-material supply, facilitating large-scale standardized extraction; their good water solubility and readily extractable active constituents suit various dosage forms-powder, extract, oral liquid, compressed candy-giving them strong industrial adaptability. More importantly, with its "quantifiably extractable" high PhGs content, C. tubulosa has become a key raw material in numerous finished medicines and health products such as Shenbao Tablets, Hongmao Medicinal Liquor and Jingjiu, and dominates Cistanche extract exports.

One often-overlooked detail is the harvesting window: raw material "before emergence" and "before bolting" contains far higher active-substance content than post-bolting product; traditional sun-drying easily leads to loss of polysaccharides and PhGs, making low-temperature and fresh-processing technologies a technical barrier for preserving activity. That is to say, even among C. tubulosa extracts, differences in origin, harvesting time, and processing technology will further widen the final product-quality gap.